Home
Clinical Trials
Treatment Of CORONAVIRUS DISE...

Treatment Of CORONAVIRUS DISEASE 2019 (COVID-19) With Anti-Sars-CoV-2 Convalescent Plasma (ASCoV2CP)

Last Updated: 2023-05-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This treatment protocol is designed to provide convalescent plasma as a therapeutic option for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Convalescent Plasma for the Treatment of COVID-19

NCT04389710

COVID-19

COMPLETED PHASE2

Convalescent Plasma in the Treatment of COVID 19

NCT04343261

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) COVID Coronavirus

COMPLETED PHASE2

SARSCoV2 (COVID-19) Convalescent Plasma (CP) Expanded Access Protocol (EAP)

NCT04374370

COVID SARSCoV2 Convalescent Plasma

NO_LONGER_AVAILABLE

Convalescent Plasma to Limit Coronavirus Associated Complications

NCT04325672

Coronavirus

WITHDRAWN PHASE2

Convalescent Plasma for Early Treatment of COVID-19

NCT04390503

SARS-CoV 2 COVID-19

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an expanded access open-label, single-arm, multi-site protocol to provide convalescent plasma as a treatment for patients diagnosed with and hospitalized for COVID-19 with symptoms ranging from mild to life-threatening. Efficacy of this treatment will not be evaluated. A single site will initially be established. When additional patients needing therapy are identified at other health care facilities, Force Health Protection (FHP) will send a protocol package, and a site will be established and approved by the Headquarters USAMRDC Institutional Review Board (HQ IRB).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Severe Acute Respiratory Syndrome Coronavirus 2

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anti-Sars-CoV-2 Convalescent Plasma

Fresh frozen plasma, Plasma Frozen for 24 hours (PF-24), or Liquid plasma

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

A patient must meet the following criteria to be included in this protocol:

* DoD personnel covered by the Force Health Protection (FHP) program under the Department of Defense Instruction (DoDI) 6200.02 (active duty service members OCONUS and CONUS) and non-DoD personnel who may be treated for COVID-19 at Military Treatment Facilities (MTFs) under the authority of DoDI 6200.03, including Military Health System (MHS) beneficiaries, patients admitted to MTFs, and patients cared for under defense support for civilian authorities (e.g. hospital ships, field hospitals deployed for the COVID-19 response).
* Laboratory confirmed COVID-19 diagnosis

* Both PCR and antigen tests are considered to be diagnostic
* Serum antibody titer testing is not considered to be diagnostic, as patients who recently recovered from COVID-19 will still test positive)
* Hospitalized with symptoms ranging from mild to life-threatening
* Informed consent provided by the patient or legally authorized representative (LAR), except in situations described in 21 CFR 50.23
* Understands and agrees to comply with planned protocol procedures

In general, adults with SARS-CoV-2 infection can be grouped into the following severity of illness categories. However, the criteria for each category may overlap or vary across clinical guidelines and clinical trials, and a patient's clinical status may change over time.

* Asymptomatic or Presymptomatic Infection: Individuals who test positive for SARS-CoV-2 using a virologic test (i.e., a nucleic acid amplification test or an antigen test) but who have no symptoms that are consistent with COVID-19.
* Mild Illness: Individuals who have any of the various signs and symptoms of COVID-19 (eg, fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell) but who do not have shortness of breath, dyspnea, or abnormal chest imaging.
* Moderate Illness: Individuals who show evidence of lower respiratory disease during clinical assessment or imaging and who have saturation of oxygen (SpO2) ≥94% on room air at sea level.
* Severe Illness: Individuals who have SpO2 \<94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) \<300 mm Hg, respiratory frequency \>30 breaths/min, or lung infiltrates \>50%.
* Critical Illness: Individuals who have respiratory failure, septic shock, and/or multiple organ dysfunction.

Eligible Sex

ALL

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.